Acceleron Pharma (XLRN) Stock Price, News & Analysis

Company Overview

Acceleron Pharma, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its product candidates include Luspatercept, designed to patients with chronic anemia associated within a wide range of blood diseases; ACE-083, designed for the treatment of focal muscle disorders; and Sotatercept, designed to treat pulmonary arterial hypertension. The company was founded by John L. Knopf and Thomas P. Maniatis in June 2003 and is headquartered in Cambridge, MA.

Key Stats

• Today's Range: $178.75 to $178.75
• 50-Day Range: $172.08 to $179.68
• 52-Week Range: $108.82 to $189.99
• Volume: N/A
• Average Volume: 572,759 shs
• Market Capitalization: $10.93 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Acceleron Pharma Stock Analysis - MarketRank™

Acceleron Pharma scored higher than 17% of companies evaluated by MarketBeat, and ranked 878th out of 934 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Acceleron Pharma.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Acceleron Pharma are expected to grow in the coming year, from ($3.95) to ($3.52) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Acceleron Pharma is -42.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Acceleron Pharma is -42.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Acceleron Pharma has a P/B Ratio of 15.23. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for XLRN.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Acceleron Pharma does not currently pay a dividend.

Dividend Growth

Acceleron Pharma does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.5 / 5
• Environmental Score: -1.02

Short Interest

There is no current short interest data available for XLRN.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

MarketBeat Follows

1 people have added Acceleron Pharma to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Acceleron Pharma insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 1.70% of the stock of Acceleron Pharma is held by insiders.

Percentage Held by Institutions

90.35% of the stock of Acceleron Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

XLRN Stock Analysis - Frequently Asked Questions

How were Acceleron Pharma's earnings last quarter?

Acceleron Pharma Inc. (NASDAQ:XLRN) released its quarterly earnings data on Thursday, November, 4th. The biopharmaceutical company reported ($1.16) earnings per share for the quarter, missing the consensus estimate of ($0.98) by $0.18. Acceleron Pharma's revenue was up 51.6% compared to the same quarter last year.

What other stocks do shareholders of Acceleron Pharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Acceleron Pharma investors own include Bristol-Myers Squibb (BMY), Gilead Sciences (GILD), Advanced Micro Devices (AMD), Meta Platforms (META), Pfizer (PFE), NVIDIA (NVDA) and Vertex Pharmaceuticals (VRTX).

Company Calendar

• Last Earnings: 11/04/2021
• Today: 3/10/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological Products, Except Diagnostic
• Sub-Industry: N/A
• Current Symbol: NASDAQ:XLRN
• CIK: 1280600
• Web: www.acceleronpharma.com
• Phone: (617) 649-9200
• Fax: 617-649-9988
• Employees: 312
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($4.21)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-166,030,000.00
• Net Margins: -226.01%
• Pretax Margin: -225.99%
• Return on Equity: -32.11%
• Return on Assets: -29.45%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 12.14
• Quick Ratio: 12.14

Sales & Book Value

• Annual Sales: $92.52 million
• Price / Sales: 118.15
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $11.74 per share
• Price / Book: 15.23

Miscellaneous

• Outstanding Shares: 61,156,000
• Free Float: 60,116,000
• Market Cap: $10.93 billion
• Optionable: Optionable
• Beta: 0.13